Optimal global spending for group A Streptococcus vaccine research and development
Abstract Group A Streptococcus (Strep A) leads to 600,000 deaths and 600 million cases of pharyngitis annually. Although long a promising target for vaccine development, how much funding should be allocated to develop a Strep A vaccine is unclear. We aim to calculate the optimal amount of global spe...
Main Authors: | Daniel Tortorice, Maddalena Ferranna, David E. Bloom |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-04-01
|
Series: | npj Vaccines |
Online Access: | https://doi.org/10.1038/s41541-023-00646-6 |
Similar Items
-
COVID-19 Vaccine Allocation: Modeling Health Outcomes and Equity Implications of Alternative Strategies
by: Maddalena Ferranna, et al.
Published: (2021-07-01) -
Factors underlying COVID-19 vaccine and booster hesitancy and refusal, and incentivizing vaccine adoption.
by: Neil G Bennett, et al.
Published: (2022-01-01) -
Social determinants of mortality from COVID-19: A simulation study using NHANES.
by: Benjamin Seligman, et al.
Published: (2021-01-01) -
Correction: Social determinants of mortality from COVID-19: A simulation study using NHANES.
by: Benjamin Seligman, et al.
Published: (2021-12-01) -
The full health, economic, and social benefits of prospective Strep A vaccination
by: Daniel Cadarette, et al.
Published: (2023-10-01)